Morepen Laboratories Ltd
MOREPENLABMorepen Laboratories Ltd
MOREPENLABPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
30.61 | 3.91 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Morepen Laboratories Limited is a pharmaceutical company. The Company operates through four segments; they are Active Pharmaceutical Ingredients (API), Domestic Formulations, Diagnostics and Over the Counter (OTC).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 486.29 | 599.19 | 610.23 | 772.21 | 862.55 | 1,200.13 | 1,557.14 | 1,423.66 | 1,704.40 | 1,704.41 | ||||||||||
Raw Materials | 303.71 | 381.14 | 365.10 | 516.38 | 567.65 | 822.13 | 1,059.36 | 939.26 | 1,531.81 | 1,531.81 | ||||||||||
Power & Fuel Cost | 7.64 | 9.84 | 11.08 | 13.18 | 12.56 | 13.00 | 18.93 | 23.78 | ||||||||||||
Employee Cost | 58.29 | 69.69 | 76.53 | 95.36 | 109.91 | 135.59 | 164.25 | 154.68 | ||||||||||||
Selling & Administrative Expenses | 43.72 | 53.46 | 61.08 | 73.30 | 81.73 | 92.40 | 102.60 | 123.94 | ||||||||||||
Operating & Other expenses | 14.56 | 19.96 | 27.99 | 2.80 | 12.70 | 6.43 | 65.01 | 96.33 | ||||||||||||
EBITDA | 58.37 | 65.10 | 68.45 | 71.19 | 78.00 | 130.58 | 146.99 | 85.67 | 172.59 | 172.60 | ||||||||||
Depreciation/Amortization | 35.20 | 33.90 | 34.32 | 39.90 | 36.91 | 30.28 | 27.64 | 27.93 | 33.47 | 33.47 | ||||||||||
PBIT | 23.17 | 31.20 | 34.13 | 31.29 | 41.09 | 100.30 | 119.35 | 57.74 | 139.12 | 139.13 | ||||||||||
Interest & Other Items | 10.50 | 7.56 | 4.36 | 2.11 | 1.98 | 1.79 | -7.37 | 1.98 | 3.71 | 3.71 | ||||||||||
PBT | 12.67 | 23.64 | 29.77 | 29.18 | 39.11 | 98.51 | 126.72 | 55.76 | 135.41 | 135.42 | ||||||||||
Taxes & Other Items | -0.13 | 0.00 | 0.18 | 0.33 | 5.53 | 1.42 | 25.02 | 17.08 | 39.25 | 39.26 | ||||||||||
Net Income | 12.80 | 23.64 | 29.59 | 28.85 | 33.58 | 97.09 | 101.70 | 38.68 | 96.16 | 96.16 | ||||||||||
EPS | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.19 | 0.78 | 1.88 | 1.88 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Morepen Laboratories Ltd | 30.61 | 3.91 | — |
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare MOREPENLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
MOREPENLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Muthoot Finance, Morepen Laboratories, and Force Motors: What the Charts Say
Gati Ltd leads losers in ‘A’ group
Morepen Laboratories Ltd leads losers in ‘A’ group
Morepen Laboratories Ltd leads gainers in ‘A’ group
Morepen Laboratories Ltd leads gainers in ‘A’ group
UCO Bank leads gainers in ‘A’ group
MSTC Ltd leads gainers in ‘A’ group
Glenmark Life Sciences Ltd leads gainers in ‘A’ group
Morepen Laboratories Ltd leads gainers in ‘A’ group
Hindustan Construction Company Ltd leads losers in ‘A’ group
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.16%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 0.34% to 0.46%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 27.22%, vs industry avg of 15.15%